Blue Print 1 and 2 studies revealed that four IHC assays (with 22C3, 28-8, SP263, and 73-10 antibody clones) were closely aligned, whereas the fifth IHC assay (with SP142 antibody clone) showed consistently fewer PD-L1 stained tumor cells. Here, CD274 is linked to neoplasm.